CBU
DNLI icon

CIBC Bancorp USA’s Denali Therapeutics DNLI Stock Holding History

CIBC Bancorp USA’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$205K Buy
+14,118
New +$203K ﹤0.01% 1253

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CIBC Bancorp USA's DNLI Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Denali Therapeutics (DNLI) in Q3 2025: 14,118 shares worth $205K. The stake represents ﹤0.01% of the portfolio and ranks #1253 among its holdings.

240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

  • CIBC Bancorp USA held 14,118 shares of Denali Therapeutics worth $205K as of Q3 2025.
  • Denali Therapeutics was a new CIBC Bancorp USA position in Q3 2025.
  • Denali Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1253 holding.
  • 240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.